Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
PEM
MCID: PRT038
MIFTS: 52

Protein-Energy Malnutrition (PEM)

Categories: Metabolic diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Protein-Energy Malnutrition

About this section

MalaCards integrated aliases for Protein-Energy Malnutrition:

Name: Protein-Energy Malnutrition 12 55 44 15 73
Proteinenergy Malnutrition 76
Pem 48

Classifications:

MalaCards categories:
Global: Metabolic diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:11801
ICD10 33 E46
ICD9CM 35 263.9
MeSH 44 D011502
NCIt 50 C34952
SNOMED-CT 68 72608005
UMLS 73 C0033677
Sources

Summaries for Protein-Energy Malnutrition

About this section
MalaCards based summary : Protein-Energy Malnutrition, also known as proteinenergy malnutrition, is related to chronic fatigue syndrome and keratomalacia, and has symptoms including cachexia and emaciation. An important gene associated with Protein-Energy Malnutrition is ALB (Albumin), and among its related pathways/superpathways are IL-1 Family Signaling Pathways and Dilated cardiomyopathy (DCM). The drugs Morphine and Naproxen have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and kidney, and related phenotypes are homeostasis/metabolism and cardiovascular system

Wikipedia : 76 Protein�??energy malnutrition (PEM) is a form of malnutrition that is defined as a range of pathological... more...

Sources

Related Diseases for Protein-Energy Malnutrition

About this section

Diseases related to Protein-Energy Malnutrition via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 254)
# Related Disease Score Top Affiliating Genes
1 chronic fatigue syndrome 31.6 IGF1 IL6 TNF
2 keratomalacia 30.8 TF TTR
3 kwashiorkor 30.5 ALB GPT TF TTR
4 marasmus 30.4 ALB IGF1 TF TTR
5 fetal macrosomia 30.2 IGF1 LEP
6 liver cirrhosis 30.1 ALB GPT LEP TF TTR
7 anorexia nervosa 30.0 IGF1 LEP TTR
8 viral hepatitis 29.8 ALB GPT TNF
9 malaria 29.8 ALB HP IL6 TF TNF
10 fatty liver disease 29.8 IL6 LEP TNF
11 meningitis 29.6 ALB IL6 TNF
12 gastroenteritis 29.6 ALB IL6 TNF
13 kidney disease 29.6 ALB IL6 TF TTR
14 viral infectious disease 29.5 GPT IL6 TNF
15 alcoholic hepatitis 29.4 ALB GPT IL6 TNF
16 deficiency anemia 29.3 ALB CP HP IL6 TF
17 chronic kidney failure 29.2 ALB IGF1 IL6 LEP TF TTR
18 diabetes mellitus 29.0 ALB CP IGF1 IL6 LEP TNF
19 liver disease 28.8 ALB CP GPT IL6 LEP TF
20 ariboflavinosis 10.3 ALB TF
21 retinitis pigmentosa 7 10.3 TF TTR
22 paramyloidosis 10.3 ALB TTR
23 hypercarotenemia and vitamin a deficiency, autosomal dominant 10.3
24 ischemia 10.3
25 epstein-barr virus hepatitis 10.3 ALB TF
26 meningitis and encephalitis 10.2 ALB CP
27 decubitus ulcer 10.2 ALB TTR
28 yellow nail syndrome 10.2 ALB TF
29 median rhomboid glossitis 10.2 TF TTR
30 aleutian mink disease 10.2 ALB TTR
31 chronic ulcer of skin 10.2 ALB TTR
32 thyroid crisis 10.2 ALB TTR
33 hyperthyroxinemia 10.2 ALB TTR
34 hypochromic microcytic anemia 10.2 CP TF
35 ancylostomiasis 10.2 CP TF
36 blind loop syndrome 10.2 ALB TTR
37 central precocious puberty 10.2 IGF1 LEP
38 autoimmune disease of peripheral nervous system 10.2 ALB TNF
39 pneumocystosis 10.2 ALB TNF
40 chronic inflammatory demyelinating polyneuropathy 10.2 HP TTR
41 compartment syndrome 10.2 ALB TNF
42 hepatic tuberculosis 10.2 ALB GPT
43 nutmeg liver 10.2 CP HP
44 hepatic coma 10.2 ALB GPT
45 cystic fibrosis 10.2
46 arthritis 10.2
47 hepatitis 10.2
48 measles 10.2
49 infantile liver failure syndrome 1 10.2 ALB GPT
50 small cell cancer of the lung 10.1

Comorbidity relations with Protein-Energy Malnutrition via Phenotypic Disease Network (PDN): (show top 50) (show all 153)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Acute Pancreatitis Acute Vascular Insufficiency of Intestine
Alcohol Abuse Alcoholic Hepatitis
Alcoholic Liver Cirrhosis Alcoholic Neuropathy
Alzheimer Disease Anorexia Nervosa
Anxiety Atrophic Gastritis
Bacteremia 2 Biliary Tract Neoplasm
Bronchiectasis Bronchitis
Bronchopneumonia Bullous Pemphigoid
Candidiasis Cardiac Arrest
Cecal Benign Neoplasm Celiac Disease 1
Cerebral Atherosclerosis Cerebral Degeneration
Cerebrovascular Disease Cholangitis
Cholecystitis Cholestasis
Chronic Intestinal Vascular Insufficiency Chronic Kidney Failure
Chronic Myocardial Ischemia Chronic Pulmonary Heart Disease
Chronic Ulcer of Skin Chylomicron Retention Disease
Colorectal Cancer Conjunctivitis
Crohn's Disease Cystitis
Decubitus Ulcer Deficiency Anemia
Dental Caries Dermatomycosis
Disseminated Intravascular Coagulation Duodenum Cancer
Dyskinesia of Esophagus Dysthymic Disorder

Graphical network of the top 20 diseases related to Protein-Energy Malnutrition:



Diseases related to Protein-Energy Malnutrition
Sources

Symptoms & Phenotypes for Protein-Energy Malnutrition

About this section

UMLS symptoms related to Protein-Energy Malnutrition:


cachexia, emaciation

MGI Mouse Phenotypes related to Protein-Energy Malnutrition:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.96 ALB CP HP IGF1 IL6 LEP
2 cardiovascular system MP:0005385 9.95 CP HP IGF1 IL6 LEP TNF
3 hematopoietic system MP:0005397 9.92 CP HP IGF1 IL6 LEP PIGR
4 digestive/alimentary MP:0005381 9.85 ALB IL6 LEP PIGR TNF TTR
5 adipose tissue MP:0005375 9.83 CP IGF1 IL6 LEP TNF
6 liver/biliary system MP:0005370 9.63 ALB CP HP IL6 LEP TNF
7 neoplasm MP:0002006 9.43 ALB HP IGF1 IL6 LEP TNF
8 renal/urinary system MP:0005367 9.1 ALB HP IGF1 IL6 LEP TTR
Sources

Drugs & Therapeutics for Protein-Energy Malnutrition

About this section

Drugs for Protein-Energy Malnutrition (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 202)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 4,Phase 3 57-27-2 5288826
2
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
3
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
4
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 52485-79-7 40400 644073
5
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
6
chenodeoxycholic acid Approved Phase 4 474-25-9 10133
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Lumefantrine Approved Phase 4 82186-77-4 6437380
10
Artemether Approved Phase 4 71963-77-4 119380 68911
11
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
12 Liver Extracts Phase 4,Phase 1,Not Applicable
13 isoleucine Phase 4
14 valine Phase 4
15 leucine Phase 4
16 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
17 Narcotics Phase 4,Phase 3,Phase 2
18 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2
20 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1
21 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Not Applicable
23 Antimetabolites Phase 4,Phase 2,Phase 1
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Cyclooxygenase Inhibitors Phase 4
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3
28 Narcotic Antagonists Phase 4,Phase 3
29 Opiate Alkaloids Phase 4
30 Gastrointestinal Agents Phase 4,Phase 2
31 Bile Acids and Salts Phase 4
32 Laxatives Phase 4
33 Anticholesteremic Agents Phase 4
34 Lipid Regulating Agents Phase 4
35 Cathartics Phase 4
36 Hypolipidemic Agents Phase 4
37 Glucagon-Like Peptide 1 Phase 4
38 Colesevelam Hydrochloride Phase 4
39 Antiprotozoal Agents Phase 4,Not Applicable
40 Artemether-lumefantrine combination Phase 4
41 Antiparasitic Agents Phase 4,Not Applicable
42 Antimalarials Phase 4
43 Artemisinine Phase 4
44 Antifungal Agents Phase 4
45 Artemisinins Phase 4
46 Anthelmintics Phase 4,Not Applicable
47
Acetaminophen Approved Phase 3,Phase 2,Phase 1 103-90-2 1983
48
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 2713 9552079
49
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
50
Lubiprostone Approved, Investigational Phase 3 136790-76-6 656719

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Egg Albumin-Based Protein Supplement Versus Renal-specific Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
2 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease Unknown status NCT02837302 Phase 4 Livact
3 Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial Completed NCT02152592 Phase 4 PCM/Oxy1;PCM/Oxy2
4 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
5 Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis-Child C Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
6 Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
7 Extended Duration Artemether-lumefantrine Treatment for Malaria in Children Recruiting NCT03453840 Phase 4 Artemether-lumefantrine
8 Conversion to Embeda With Rescue Trial Terminated NCT01179191 Phase 4 morphine sulfate and naltrexone hydrochloride (EMBEDA)
9 Use of Morphine Gel Topically in Patients With Stage 2-3 Wounds Unknown status NCT00755989 Phase 3 morphine topical gel;placebo
10 Post-Approval Clinical Trial of the PCM® Cervical Disc Completed NCT01905930 Phase 3
11 PCM Cervical Disc System Completed NCT00578812 Phase 3
12 Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer Completed NCT01875393 Phase 3 TOOKAD® Soluble
13 Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. Completed NCT01310894 Phase 3 TOOKAD® Soluble
14 Newborn Kit to Save Lives and Brains in Kenya Completed NCT02208960 Phase 3
15 Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients Completed NCT00561093 Phase 3 pentoxiphylline;Placebo pill imitating pentoxiphylline
16 Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone Completed NCT00597428 Phase 3 Lubiprostone;Placebo
17 Safety and Efficacy Study of Xyrem® (Sodium Oxybate) in Subjects With Fibromyalgia. Completed NCT00423605 Phase 3 Xyrem®
18 A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia Completed NCT00371137 Phase 3 Xyrem®;Placebo
19 Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain Completed NCT00312572 Phase 3 Buprenorphine transdermal patch
20 Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study) Not yet recruiting NCT03664141 Phase 3 Cannabis oil;Placebo/ Regular Oil
21 Paracetamol for Intrapartum Analgesia Unknown status NCT02578251 Phase 2 Paracetamol;Pethidine
22 Whole Body Cooling Using Phase Changing Material Unknown status NCT01138176 Phase 1, Phase 2
23 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
24 Study of Efficacy of Induction Chemotherapy With Gemcitabine and Carboplatin for Operable Non-small-cell Lung Cancer Before Surgery Unknown status NCT00563160 Phase 2 gemcitabine, carboplatin
25 Violence and Stress Assessment (ViStA) Project to Improve Post Traumatic Stress Disorder Management in Primary Care Completed NCT01401101 Phase 2
26 Collection of Transplant Stem Cells for Plasma Cell Myeloma Completed NCT01547806 Phase 2 Filgrastim;Plerixafor
27 Study Using WST11 in Patients With Localized Prostate Cancer Completed NCT00975429 Phase 2 WST11;WST11
28 Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer Completed NCT00946881 Phase 1, Phase 2 WST 11 -mediated -VTP
29 Study of WST11 in Patients With Localized Prostate Cancer Completed NCT00707356 Phase 2 WST11
30 Evaluation of Cortisol Resistance in Young Sedentary and Endurance-Trained Men Completed NCT01294319 Phase 2 Mifepristone;Placebo;Spironolactone;Combined;Dexamethasone
31 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting NCT03414034 Phase 2 Onvansertib;Abiraterone;Prednisone
32 Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML). Recruiting NCT03303339 Phase 1, Phase 2 Onvansertib;Cytarabine;Decitabine
33 Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer. Recruiting NCT03315754 Phase 2 TOOKAD Soluble 4 mg/kg
34 Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer Recruiting NCT03157128 Phase 1, Phase 2 LOXO-292
35 Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma Terminated NCT00557830 Phase 2 Sorafenib Escalated Dose;Sorafenib Standard Dose
36 Macrophage Markers, Soluble CD163 (sCD163) and Soluble CD206 (sCD206) in Paracetamol Overdose Completed NCT03679442 Phase 1 N-acetylcysteine
37 Acceptability and Efficacy of 'Fish Surimi Peptide' in Under Five Children Suffering From Moderate Acute Malnutrition Completed NCT02272543 Phase 1
38 A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer Terminated NCT00779311 Phase 1 sorafenib;bevacizumab;mFOLFOX6 regimen
39 Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project) Unknown status NCT02273206 Not Applicable
40 The Impact of Perioperational Malnutrition on the Cost on Gastroenterological Cancer Patients Unknown status NCT00987883
41 Effectiveness of Safe Drinking Water in Treatment of Severe Acute Malnutrition (Pakistan) Unknown status NCT02751476 Not Applicable
42 Evaluation of the Effectiveness of a Protein Pulse-Feeding Pattern in Elderly Patients Completed NCT00135590 Not Applicable
43 Clinical Performance of the Embrace Isothermal Mattress Completed NCT01425086
44 Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Completed NCT01873963
45 Study of Antioxidants and Oxidants in Malnourished Children Completed NCT00069134 Not Applicable
46 Enhancing HIV Prevention by Using Behavioral Intervention Among HIV-Infected Men Completed NCT00231972 Not Applicable
47 Energy Dense Formula to People Living in Old Peoples Home Completed NCT01259999 Not Applicable
48 aCGH Impacts Survival in Plasma Cell PTLD Completed NCT02984215
49 Role of Nutrition in Patients Over 75 Years of Age With Stroke Completed NCT02856009 Not Applicable
50 Bioelectrical Impedance Vector Analysis in Cirrhotic Patients Completed NCT01603953

Search NIH Clinical Center for Protein-Energy Malnutrition

Cochrane evidence based reviews: protein-energy malnutrition

Sources

Genetic Tests for Protein-Energy Malnutrition

About this section
Sources

Anatomical Context for Protein-Energy Malnutrition

About this section

MalaCards organs/tissues related to Protein-Energy Malnutrition:

41
Liver, Bone, Kidney, Brain, Thyroid, Testes, Heart
Sources

Publications for Protein-Energy Malnutrition

About this section

Articles related to Protein-Energy Malnutrition:

(show top 50) (show all 707)
# Title Authors Year
1
Identifying reliable predictors of protein-energy malnutrition in hospitalized frail older adults: A prospective longitudinal study. ( 29579571 )
2018
2
Protein-Energy Malnutrition Exacerbates Stroke-Induced Forelimb Abnormalities and Dampens Neuroinflammation. ( 29397529 )
2018
3
Why Is the Skeleton Still in the Hospital Closet? A Look at the Complex Aetiology of Protein-Energy Malnutrition and Its Implications for the Nutrition Care Team. ( 29300418 )
2018
4
Prospective associations of poor diet quality with long-term incidence of protein-energy malnutrition in community-dwelling older adults: the Health, Aging, and Body Composition (Health ABC) Study. ( 29529142 )
2018
5
A systematic review and meta-analysis of the criterion validity of nutrition assessment tools for diagnosing protein-energy malnutrition in the older community setting (the MACRo study). ( 29102322 )
2018
6
Zinc deficiency and severe protein-energy malnutrition in a child with atopic eczema. ( 30062797 )
2018
7
A systematic review, meta-analysis and meta-regression of the prevalence of protein-energy malnutrition: associations with geographical region and sex. ( 30188972 )
2018
8
Honey can repairing damage of liver tissue due to protein energy malnutrition through induction of endogenous stem cells. ( 28717326 )
2017
9
Protein energy malnutrition alters mucosal IgA responses and reduces mucosal vaccine efficacy in mice. ( 28860040 )
2017
10
Protein blend ingestion before allogeneic stem cell transplantation improves protein-energy malnutrition in patients with leukemia. ( 28964569 )
2017
11
Genetic Engineering: A Possible Strategy for Protein-Energy Malnutrition Regulation. ( 28828714 )
2017
12
An Adjuvanted A(H5N1) Subvirion Vaccine Elicits Virus-Specific Antibody Response and Improves Protection Against Lethal Influenza Viral Challenge in Mouse Model of Protein Energy Malnutrition. ( 28934453 )
2017
13
The Arid Melancholy-Netherton Syndrome With Protein Energy Malnutrition. ( 27190931 )
2016
14
Protein-energy malnutrition is frequent and precocious in children with cri du chat syndrome. ( 26872355 )
2016
15
Convergence of a diabetes mellitus, protein energy malnutrition, and TB epidemic: the neglected elderly population. ( 27456231 )
2016
16
Protein energy malnutrition associates with different types of hearing impairments in toddlers: Anemia increases cochlear dysfunction. ( 27240492 )
2016
17
Protein-energy malnutrition in the rehabilitation setting: Evidence to improve identification. ( 26921933 )
2016
18
Does protein energy malnutrition affect the outcome in Tunisian cirrhotic patients? ( 27532543 )
2016
19
Serum hyaluronic acid predicts protein-energy malnutrition in chronic hepatitis C. ( 27311000 )
2016
20
Prognostic significance of low skeletal muscle mass compared with protein-energy malnutrition in liver cirrhosis. ( 27862791 )
2016
21
Factors Associated With Protein-energy Malnutrition in Chronic Liver Disease: Analysis Using Indirect Calorimetry. ( 26765430 )
2016
22
Protein-energy malnutrition at mid-adulthood does not imprint long-term metabolic consequences in male rats. ( 26133298 )
2015
23
Serum vitamin D status in children with protein-energy malnutrition admitted to a national referral hospital in Uganda. ( 26346815 )
2015
24
Leucine Supplementation Improves Acquired Growth Hormone Resistance in Rats with Protein-Energy Malnutrition. ( 25909895 )
2015
25
Protein-energy malnutrition: a risk factor for various ailments. ( 24915388 )
2015
26
Evaluation of dental age in protein energy malnutrition children. ( 26538919 )
2015
27
Seroprevalence rate of Poliovirus antibodies among the Healthy and Protein Energy Malnutrition children. ( 26101500 )
2015
28
Protein Energy Malnutrition during Vaccination Has Limited Influence on Vaccine Efficacy but Abolishes Immunity if Administered during Mycobacterium tuberculosis Infection. ( 25754202 )
2015
29
Protein-Energy Malnutrition Causes Deficits in Motor Function in Adult Male Rats. ( 26423735 )
2015
30
Protein Energy-Malnutrition: Does the In Vitro Zinc Sulfate Supplementation Improve Chromosomal Damage Repair? ( 25262017 )
2014
31
Free radicals and antioxidant status in protein energy malnutrition. ( 24790610 )
2014
32
Protein energy malnutrition increases arginase activity in monocytes and macrophages. ( 25392710 )
2014
33
Maternal protein-energy malnutrition during early pregnancy in sheep impacts the fetal ornithine cycle to reduce fetal kidney microvascular development. ( 25077559 )
2014
34
Prevalence of protein-energy malnutrition in hospital patients over 75 years of age admitted for hip fracture. ( 24998085 )
2014
35
Protein energy malnutrition in India: the plight of our under five children. ( 24791240 )
2014
36
Protein-energy Malnutrition in Goitrous Schoolchildren of Isfahan, Iran. ( 24932384 )
2014
37
Determinants of protein-energy malnutrition in community dwelling older adults: A systematic review of observational studies. ( 25257179 )
2014
38
Protein-energy malnutrition developing after global brain ischemia induces an atypical acute-phase response and hinders expression of GAP-43. ( 25259609 )
2014
39
Missed opportunities in the diagnosis and management of protein energy malnutrition among children under 5 years in Wakiso district, Uganda. ( 25035810 )
2013
40
Acquired protein energy malnutrition in glutaric acidemia. ( 23330977 )
2013
41
Effect of a probiotic fermented milk on the thymus in Balb/c mice under non-severe protein-energy malnutrition. ( 23286742 )
2013
42
A narrative review of recent progress in understanding the relationship between tuberculosis and protein energy malnutrition. ( 23942176 )
2013
43
Rutin (quercetin rutinoside) induced protein-energy malnutrition in chronic kidney disease, but quercetin acted beneficially. ( 23876017 )
2013
44
Hematologic and Bone Marrow Changes in Children with Protein-Energy Malnutrition. ( 23987917 )
2013
45
Protein energy malnutrition decreases immunity and increases susceptibility to influenza infection in mice. ( 22949306 )
2013
46
Cystic fibrosis: from protein-energy malnutrition to obesity with dyslipidemia. ( 24800027 )
2013
47
Porcine placenta mitigates protein-energy malnutrition-induced fatigue. ( 24035056 )
2013
48
Protein-energy malnutrition induces an aberrant acute-phase response and modifies the circadian rhythm of core temperature. ( 23855272 )
2013
49
Protein-energy malnutrition alters IgA responses to rotavirus vaccination and infection but does not impair vaccine efficacy in mice. ( 24200975 )
2013
50
A comparison of the full Mini Nutritional Assessment, short-form Mini Nutritional Assessment, and Subjective Global Assessment to predict the risk of protein-energy malnutrition in patients on peritoneal dialysis: a cross-sectional study. ( 23000089 )
2013
Sources

Variations for Protein-Energy Malnutrition

About this section
Sources

Expression for Protein-Energy Malnutrition

About this section
Search GEO for disease gene expression data for Protein-Energy Malnutrition.
Sources

Pathways for Protein-Energy Malnutrition

About this section

Pathways related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
IL-1 Family Signaling Pathways 65
Show member pathways
 11.97 CP IL6 TNF
2
Dilated cardiomyopathy (DCM) 37
Show member pathways
 11.95 IGF1 IL6 TNF
3
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.91 IL6 TF TNF
4
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.79 ALB IGF1 IL6
5
Spinal Cord Injury 1
11.73 IL6 LEP TNF
6
HIF-1 signaling pathway 37
11.63 IGF1 IL6 TF
7
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.46 IGF1 IL6 TNF
8
HIF-1-alpha transcription factor network 1
11.39 CP LEP TF
9
Adipogenesis 1
11.38 IGF1 IL6 LEP TNF
10
Lung fibrosis 1
11.34 IGF1 IL6 TNF
11
amb2 Integrin signaling 1
11.18 HP IL6 TNF
12
Differentiation Pathway 1
11.11 IGF1 IL6 TF
13
Antifolate resistance 37
11.06 IL6 TNF
14
Cytokines and Inflammatory Response 1
11.02 IL6 TNF
15
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.99 IGF1 IL6 TNF
16
Overview of nanoparticle effects 1
10.79 IL6 TNF
17
Transcription factor regulation in adipogenesis 1
10.14 IL6 LEP TNF
Sources

GO Terms for Protein-Energy Malnutrition

About this section

Cellular components related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.87 ALB CP GPT HP PIGR TF
2 extracellular region GO:0005576 9.65 ALB CP HP IGF1 IL6 LEP
3 endoplasmic reticulum lumen GO:0005788 9.56 ALB CP IL6 TF
4 blood microparticle GO:0072562 9.46 ALB CP HP TF
5 extracellular space GO:0005615 9.36 ALB CP GPT HP IGF1 IL6

Biological processes related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.9 ALB IGF1 IL6 LEP
2 post-translational protein modification GO:0043687 9.78 ALB CP IL6 TF
3 positive regulation of MAPK cascade GO:0043410 9.7 IGF1 IL6 LEP
4 platelet degranulation GO:0002576 9.67 ALB IGF1 TF
5 regulation of signaling receptor activity GO:0010469 9.65 IGF1 IL6 LEP TNF TTR
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.63 IGF1 LEP TNF
7 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.61 IGF1 IL6 LEP
8 positive regulation of cytokine production GO:0001819 9.59 LEP TNF
9 positive regulation of JAK-STAT cascade GO:0046427 9.58 IL6 LEP
10 negative regulation of neurogenesis GO:0050768 9.58 IL6 TNF
11 positive regulation of chemokine production GO:0032722 9.57 IL6 TNF
12 leukocyte tethering or rolling GO:0050901 9.56 LEP TNF
13 positive regulation of calcineurin-NFAT signaling cascade GO:0070886 9.55 IGF1 TNF
14 positive regulation of glial cell proliferation GO:0060252 9.54 IL6 TNF
15 negative regulation of glucose import GO:0046325 9.51 LEP TNF
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.5 IGF1 IL6 TNF
17 positive regulation of neuroinflammatory response GO:0150078 9.4 IL6 TNF
18 bone mineralization involved in bone maturation GO:0035630 9.37 IGF1 LEP
19 retina homeostasis GO:0001895 9.33 ALB PIGR TF
20 negative regulation of lipid storage GO:0010888 9.13 IL6 LEP TNF
21 cellular protein metabolic process GO:0044267 9.1 ALB CP IGF1 IL6 TF TTR

Molecular functions related to Protein-Energy Malnutrition according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antioxidant activity GO:0016209 8.96 ALB HP
2 hormone activity GO:0005179 8.8 IGF1 LEP TTR
Sources

Sources for Protein-Energy Malnutrition

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....